JZUS - Journal of Zhejiang University SCIENCE

Journal of Zhejiang University SCIENCE B 2014 Vol.15 No.6 P.533-539

Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro *

Author(s): Jing-yao Pang¹, Kui-jun Zhao¹, Jia-bo Wang², Zhi-jie Ma¹, Xiao-he Xiao³
Affiliation(s): 1. Clinical Pharmacy Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; more
Corresponding email(s): pharm_sci@126.com
Key Words: Epigallocatechin-3-gallate, Hepatitis B virus (HBV), Antiviral activity, HepG2 2.2.15, Lamivudine

Share this article to： More <<< Previous Article \|Next Article >>>

Jing-yao Pang, Kui-jun Zhao, Jia-bo Wang, Zhi-jie Ma, Xiao-he Xiao. Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro[J]. Journal of Zhejiang University Science B, 2014, 15(6): 533-539.

@article{title="Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro",
author="Jing-yao Pang, Kui-jun Zhao, Jia-bo Wang, Zhi-jie Ma, Xiao-he Xiao",
journal="Journal of Zhejiang University Science B",
volume="15",
number="6",
pages="533-539",
year="2014",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1300307"
}

%0 Journal Article
%T Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro
%A Jing-yao Pang
%A Kui-jun Zhao
%A Jia-bo Wang
%A Zhi-jie Ma
%A Xiao-he Xiao
%J Journal of Zhejiang University SCIENCE B
%V 15
%N 6
%P 533-539
%@ 1673-1581
%D 2014
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1300307

TY - JOUR
T1 - Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro
A1 - Jing-yao Pang
A1 - Kui-jun Zhao
A1 - Jia-bo Wang
A1 - Zhi-jie Ma
A1 - Xiao-he Xiao
J0 - Journal of Zhejiang University Science B
VL - 15
IS - 6
SP - 533
EP - 539
%@ 1673-1581
Y1 - 2014
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1300307

Abstract
Chinese Summary
Academic Network
Reviewer Comment

Abstract: Although several antiviral drugs and vaccines are available for use against hepatitis B virus (HBV), hepatitis caused by HBV remains a major public health problem worldwide, which has not yet been resolved, and new anti-HBV drugs are in great demand. The present study was performed to investigate the anti-HBV activity of epigallocatechin-3-gallate (EGCG), a natural-origin compound, in hepG2 2.2.15 cells. The antiviral activity of EGCG was examined by detecting the levels of HBsAg and HBeAg in the supernatant and extracellular HBV DNA. EGCG effectively suppressed the secretion of HBsAg and HBeAg from hepG2 2.2.15 cells in a dose- and time-dependent manner, and it showed stronger effects at the level of 0.11–0.44 μmol/ml (50–200 μg/ml) than lamivudine (3TC) at 0.87 μmol/ml (200 μg/ml). EGCG also suppressed the amount of extracellular HBV DNA. The data indicated that EGCG possessed anti-HBV activity and suggested the potential of EGCG as an effective anti-HBV agent with low toxicity.

绿茶多酚表没食子儿茶素没食子酸酯（EGCG）体外对抗乙肝病毒复制的能力

研究目的：乙肝是尚未解决的公众健康问题，需要开发新型抗病毒药物。本研究拟从天然植物绿茶中寻找有效、经济、毒副作用低的抗乙肝病毒药物。
创新要点：首次以HepG2 2.2.15细胞为载体，发现EGCG对乙肝病毒HBsAg、HBeAg和HBV DNA的选择性作用。
研究方法：采用酶联免疫吸附实验（ELISA）检测细胞上清中HBsAg和HBeAg的含量，采用反转录聚合酶链反应（RT-PCR）检测上清和细胞内HBV DNA的含量。
重要结论：EGCG的浓度在0.11~0.44 μmol/ml（即50~200 μg/ml）的范围内能有效抑制HepG2 2.2.15细胞中HBsAg和HBeAg的分泌，其效果甚至优于浓度为0.87 μmol/ml（即200 μg/ml）的拉米夫定（3TC），并且具有时间和剂量依赖性。同时，EGCG也能抑制胞外HBV DNA的表达。研究结果表明，EGCG具有良好抗病毒活性和低毒副作用，有望开发成为一种新的抗病毒药物。

关键词：EGCG；乙肝病毒（HBV）；抗病毒；HepG2 2.2.15细胞；拉米夫定

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

References

[1] Abramovits, W., Gupta, A.K., 2010. Veregen (sinecatechins ointment) 15%. Skinmed, 8(1):46-49.

[2] Ciesek, S., von Hahn, T., Colpitts, C.C., 2011. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology, 54(6):1947-1955.

[3] Cui, X.Y., Inagaki, Y., Xu, H.L., 2010. Anti-hepatitis B virus activities of cinobufacini and its active components bualin and cinobufagin in HepG2.2.15 cells. Biol Pharm Bull, 33(10):1728-1732.

[4] Fassina, G., Buffa, A., Benelli, R., 2002. Polyphenolic antioxidant (−)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. AIDS, 16(6):939-941.

[5] Feld, J., Locarnini, S., 2002. Antiviral therapy for hepatitis B virus infections: new targets and technical challenges. J Clin Virol, 25(3):267-283.

[6] Harada, S., Haneda, E., Maekawa, T., 1999. Casein kinase II (CK-II)-mediated stimulation of HIV-1 reverse transcriptase activity and characterization of selective inhibitors in vitro . Biol Pharm Bull, 22(10):1122-1126.

[7] Hastak, K., Gupta, S., Ahmad, N., 2003. Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene, 22(31):4851-4859.

[8] Kawai, K., Tsuno, N.H., Kitayama, J., 2004. Epigallocatechin gallate attenuates adhesion and migration of CD8⁺ T cells by binding to CD11b. J Allergy Clin Immunol, 113(6):1211-1217.

[9] Kawai, K., Tsuno, N.H., Kitayama, J., 2005. Epigallocatechin gallate induces apoptosis of monocytes. J Allergy Clin Immunol, 115(1):186-191.

[10] Khan, N., Afaq, F., Saleem, M., 2006. Targeting multiple signaling pathways by green tea polyphenol (−)-epigallocatechin-3-gallate. Cancer Res, 66(5):2500-2555.

[11] Nakane, H., Ono, K., 1989. Differential inhibition of HIV-reverse transcriptase and various DNA and RNA polymerases by some catechin derivatives. Nucl Acids Symp Ser, (21):115-116.

[12] Pang, R., Tao, J.Y., Zhang, S.L., 2010. In vitro antiviral activity of lutein against hepatitis B virus. Phytother Res, 24(11):1627-1630.

[13] Park, N.H., Song, I.H., Chung, Y.H., 2006. Chronic hepatitis B in hepatocarcinogenesis. J Postgrad Med J, 82(970):507-515.

[14] Perrillo, R.P., 2005. Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis, 25(S1):20-28.

[15] Singh, R., Ahmed, S., Islam, N., 2002. Epigallocatechin-3-gallate inhibits interleukin-1β-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. Arthritis Rheum, 46(8):2079-2086.

[16] Steinmann, J., Buer, J., Pietschmann, T., 2013. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Brit J Pharmacol, 168(5):1059-1073.

[17] Stickel, F., Schuppan, D., 2007. Herbal medicine in the treatment of liver diseases. Dig Liver Dis, 39(4):293-304.

[18] Xu, J., Wang, J., Deng, F., 2008. Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro . Antivir Res, 78(3):242-249.

[19] Yamaguchi, K., Honda, M., Ikigai, H., 2002. Inhibitory effects of (−)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antivir Res, 53(1):19-34.

[20] Zhang, L., Wang, G., Hou, W., 2010. Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology, 51(2):690-698.

[21] Zhen, M.C., Wang, Q., Huang, X.H., 2007. Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative damage and preventive effects on carbon tetrachloride-induced hepatic fibrosis. J Nutr Biochem, 18(12):795-805.

Similar articles

- Go to

绿茶多酚表没食子儿茶素没食子酸酯（EGCG）体外对抗乙肝病毒复制的能力

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

References